SCHEMBL751945

SCHEMBL751945

CCOC(=O)c1cc(N)n(-c2cc(SC)nc(C)n2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 5/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 2/20 0.38
MEN1 O00255 2/20 0.38
HPGD P15428 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
MPO P05164 1/20 0.38
POLB P06746 1/20 0.37
MAPK1 P28482 1/20 0.37
CA9 Q16790 2/20 0.37
CYP1A2 P05177 1/20 0.37
LMNA P02545 1/20 0.36
PDE4D Q08499 1/20 0.36
CHRNA7 P36544 2/20 0.36
GABRP O00591 1/20 0.36
GABRD O14764 1/20 0.36
GABRA1 P14867 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11026681 0.84 ALDH1A1 (0.34) KMT2AGAAALDH1A1KDM4EMEN1
SCHEMBL753745 0.78 TSHR (0.59) KMT2AMAPTALDH1A1KDM4EMEN1
SCHEMBL754183 0.77 SLC2A1 (0.35) KMT2AGAAMAPTKDM4EHPGD
SCHEMBL4700330 0.72 HPGD (0.60) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL2835335 0.71 KMT2A (0.65) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL14357202 0.71 CA9 (0.61) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL8003314 0.70 LMNA (0.47) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL12952509 0.70 KMT2A (0.46) KMT2AGAAMAPTALDH1A1KDM4E
SCHEMBL4701523 0.69 CHRNA7 (0.62) KMT2AGAAMAPTALDH1A1MEN1
SCHEMBL11656484 0.69 CHRNA7 (0.62) KMT2AGAAMAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors AMGEN INC. (US) 2012-07-26 US disclosed
EP-2430013-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS Amgen, Inc (US) 2012-03-21 EP disclosed
WO-2010132598-A1 HETEROARYL COMPOUNDS AS PIKK INHIBITORS AMGEN INC. (US) 2010-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190666-A1 Heteroaryl Compounds as PIKK Inhibitors PIK3CA, PIKFYVE, PIK3CD KMT2A 2120/4885GAA 684/4885MAPT 3169/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.